150 related articles for article (PubMed ID: 7641216)
21. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
[TBL] [Abstract][Full Text] [Related]
22. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
23. Complement-mediated killing of microtumors in vitro.
Hakulinen J; Meri S
Am J Pathol; 1998 Sep; 153(3):845-55. PubMed ID: 9736033
[TBL] [Abstract][Full Text] [Related]
24. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
25. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens.
Hellström I; Garrigues HJ; Garrigues U; Hellström KE
Cancer Res; 1990 Apr; 50(7):2183-90. PubMed ID: 1690595
[TBL] [Abstract][Full Text] [Related]
26. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
27. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
Sier CF; Gelderman KA; Prins FA; Gorter A
Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
[TBL] [Abstract][Full Text] [Related]
28. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
29. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
[TBL] [Abstract][Full Text] [Related]
30. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
31. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
32. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Klausz K; Berger S; Lammerts van Bueren JJ; Derer S; Lohse S; Dechant M; van de Winkel JG; Peipp M; Parren PW; Valerius T
Cancer Sci; 2011 Oct; 102(10):1761-8. PubMed ID: 21718386
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.
Hellström I; Beaumier PL; Hellström KE
Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7059-63. PubMed ID: 3462743
[TBL] [Abstract][Full Text] [Related]
35. Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.
Song JX; Cao WL; Li FQ; Shi LN; Jia X
Med Oncol; 2012 Dec; 29(4):2923-31. PubMed ID: 22198696
[TBL] [Abstract][Full Text] [Related]
36. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
37. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies against leucoagglutinin-reactive human T lymphocyte surface components. Two antibodies which inhibit cell-mediated cytotoxicity at a post-binding stage.
Vargas-Cortes M; Hammarström ML; Hammarström S; Hellström U; Perlmann P
Eur J Immunol; 1986 Jul; 16(7):795-801. PubMed ID: 3522246
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
40. A monoclonal antibody (RH1-38) which inhibits multiple systems of cell-mediated cytotoxicity--I. Identification of a novel epitope on a killer cell surface bimolecular complex important in the cytotoxic response.
Hall RE
Mol Immunol; 1985 Jul; 22(7):757-64. PubMed ID: 2412110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
